PRECLINICAL TOXICITY STUDY OF A NEW ANTIREFLUX ANTACID DRUG "ALGINOMAX"
Preclinical toxicological study of safety of antireflux antacid drug «AlginoMAX» were carried out. No animals were lost after «AlginoMAX» acute oral administration at a maximum dose of 5500 mg/kg in male and female rats and mice. Also it does not cause lethality in male and female rats at a single intraperitoneal introduction at the dose of 1300 mg/kg. «AlginoMAX» administered per os during 2 months in rats (both males and females) at the doses of 500, 1000 and 2000 mg/kg induced no irreversible pathological changes in organs and systems studied. The tested antireflux antacid drug «AlginoMAX» exhibited no allergenic activity, local irritation and did not affect generative function and the antenatal and postnatal development of progeny.